. 2017 Feb 11;4(1):ofx028. doi: 10.1093/ofid/ofx028

Table 2.

Incidence of HBV Reactivation and Clinical Events in Patients Receiving IFN-Free DAA Therapy

IFN-Free DAA Treatment Status	HBV Serology			HBV Reactivation, n/N (%)	HBV-Related ALT Flare, n/N (%)	HBV-Related Hepatic Decompensation, n/N (%)	HBsAg Seroreversion, n/N (%)
IFN-Free DAA Treatment Status	HBsAg	Anti-HBs	Anti-HBc	HBV Reactivation, n/N (%)	HBV-Related ALT Flare, n/N (%)	HBV-Related Hepatic Decompensation, n/N (%)	HBsAg Seroreversion, n/N (%)
Patients completing 12 weeks of therapy (N = 93)	+	−	+	2/12 (16.7)	0/12 (0)	0/12 (0)	-
	−	−	+	0/46 (0)	0/46 (0)	0/46 (0)	0/46 (0)
	−	+	+	0/35 (0)	0/35 (0)	0/35 (0)	0/35 (0)
Patients completing 12 weeks of off-therapy follow-up (N = 86)	+	−	+	2/12 (16.7)	0/12 (0)	0/12 (0)	-
	−	−	+	0/43 (0)	0/43 (0)	0/43 (0)	0/43 (0)
	−	+	+	0/31 (0)	0/31 (0)	0/31 (0)	0/31 (0)

Abbreviations: ALT, alanine aminotransferase; anti-HBc, hepatitis B virus core antibody; anti-HBs, hepatitis B virus surface antibody; DAA, direct-acting antiviral agent; HBsAg, hepatitis B surface agent; HBV, hepatitis B virus; IFN, interferon.